Department of Nanobiotechnology, Faculty of Biological Sciences, Tarbiat Modares University, Tehran 14117-13116, Iran.
Centro de Investigación Príncipe Felipe, Targeted Therapies on Cancer and Inflammation Laboratory, 46012 Valencia, Spain.
Int J Mol Sci. 2022 Jan 31;23(3):1651. doi: 10.3390/ijms23031651.
Inflammasomes are multiprotein complexes that represent critical elements of the inflammatory response. The dysregulation of the best-characterized complex, the NLRP3 inflammasome, has been linked to the pathogenesis of diseases such as multiple sclerosis, type 2 diabetes mellitus, Alzheimer's disease, and cancer. While there exist molecular inhibitors specific for the various components of inflammasome complexes, no currently reported inhibitors specifically target NLRP3 homo-oligomerization. In the present study, we describe the identification of QM380 and QM381 as NLRP3 homo-oligomerization inhibitors after screening small molecules from the MyriaScreen library using a split-luciferase complementation assay. Our results demonstrate that these NLRP3 inhibitors interfere with ASC speck formation, inhibit pro-inflammatory cytokine IL1-β release, and decrease pyroptotic cell death. We employed spectroscopic techniques and computational docking analyses with QM380 and QM381 and the PYD domain to confirm the experimental results and predict possible mechanisms underlying the inhibition of NLRP3 homo-interactions.
炎症小体是多蛋白复合物,是炎症反应的关键组成部分。功能失调的最典型的复合物,NLRP3 炎症小体,与多种疾病的发病机制有关,如多发性硬化症、2 型糖尿病、阿尔茨海默病和癌症。虽然存在针对炎症小体复合物的各种成分的分子抑制剂,但目前没有报道专门针对 NLRP3 同源寡聚化的抑制剂。在本研究中,我们描述了在使用分裂萤光素酶互补测定法从小 MyriaScreen 文库筛选小分子后,鉴定出 QM380 和 QM381 作为 NLRP3 同源寡聚化抑制剂。我们的结果表明,这些 NLRP3 抑制剂干扰 ASC 斑点形成,抑制促炎细胞因子 IL1-β 的释放,并减少细胞焦亡死亡。我们使用光谱技术和计算对接分析与 QM380 和 QM381 以及 PYD 结构域,以确认实验结果并预测抑制 NLRP3 同源相互作用的可能机制。